20.71
2.04 (10.93%)
| Penutupan Terdahulu | 18.67 |
| Buka | 18.41 |
| Jumlah Dagangan | 1,731,828 |
| Purata Dagangan (3B) | 980,114 |
| Modal Pasaran | 1,749,568,640 |
| Harga / Jualan (P/S) | 38.01 |
| Harga / Buku (P/B) | 3.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Keuntungan | 3.86% |
| Margin Operasi (TTM) | 51.85% |
| EPS Cair (TTM) | 0.120 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7,882.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.21% |
| Nisbah Semasa (MRQ) | 5.61 |
| Aliran Tunai Operasi (OCF TTM) | 34.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 40.54 M |
| Pulangan Atas Aset (ROA TTM) | -0.40% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Monte Rosa Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.10 |
|
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.73% |
| % Dimiliki oleh Institusi | 101.33% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CHAMPOUX JENNIFER | - | 18.41 | -2,176 | -40,060 |
| TOWNSON SHARON | - | 18.41 | -3,000 | -55,230 |
| Jumlah Keseluruhan Kuantiti Bersih | -5,176 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -95,290 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 18.41 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TOWNSON SHARON | Pegawai | 17 Jun 2026 | Jual automatik (-) | 3,000 | 18.41 | 55,230 |
| TOWNSON SHARON | Pegawai | 17 Jun 2026 | Pelaksanaan pilihan | 3,000 | - | - |
| CHAMPOUX JENNIFER | Pegawai | 17 Jun 2026 | Jual automatik (-) | 2,176 | 18.41 | 40,060 |
| CHAMPOUX JENNIFER | Pegawai | 17 Jun 2026 | Pelaksanaan pilihan | 2,176 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |